ICOSAVAX INC(NASDAQ:ICVX) stock Fundamental Analysis

Fundamental Rating

Overall ICVX gets a fundamental rating of 3 out of 10. We evaluated ICVX against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ICVX as it has an excellent financial health rating, but there are worries on the profitability. ICVX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

ICVX had negative earnings in the past year.

In the past year ICVX has reported a negative cash flow from operations.

1.2 Ratios

ICVX's Return On Assets of -38.48% is fine compared to the rest of the industry. ICVX outperforms 62.67% of its industry peers.

The Return On Equity of ICVX (-41.61%) is better than 71.96% of its industry peers.

		Industry Rank	Sector Rank
ROA	-38.48%
ROE	-41.61%
ROIC	N/A

ROA(3y)-59.36%

ROA(5y)N/A

ROE(3y)-206.85%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ICVX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ICVX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ICVX has more shares outstanding

ICVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ICVX has an Altman-Z score of 22.57. This indicates that ICVX is financially healthy and has little risk of bankruptcy at the moment.

ICVX has a better Altman-Z score (22.57) than 92.74% of its industry peers.

ICVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	22.57

ROIC/WACCN/A

WACC10.99%

2.3 Liquidity

ICVX has a Current Ratio of 18.10. This indicates that ICVX is financially healthy and has no problem in meeting its short term obligations.

ICVX has a better Current ratio (18.10) than 91.55% of its industry peers.

A Quick Ratio of 18.10 indicates that ICVX has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 18.10, ICVX belongs to the top of the industry, outperforming 91.55% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	18.1
Quick Ratio	18.1

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ICVX have decreased by -1.83% in the last year.

The Revenue for ICVX has decreased by -100.00% in the past year. This is quite bad

EPS 1Y (TTM)-1.83%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%20%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

ICVX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.96% yearly.

The Revenue is expected to grow by 194.45% on average over the next years. This is a very strong growth

EPS Next Y5.52%

EPS Next 2Y3.44%

EPS Next 3Y-1.53%

EPS Next 5Y18.96%

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y3.57%

Revenue Next 5Y194.45%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ICVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ICVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y3.44%

EPS Next 3Y-1.53%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ICVX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ICOSAVAX INC

NASDAQ:ICVX (2/16/2024, 8:05:55 PM)

After market: 15.39 +0.08 (+0.52%)

15.31

-0.14 (-0.91%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-14 2023-11-14/amc

Earnings (Next)N/A N/A

Inst Owners1.88%

Inst Owner Change-0.02%

Ins Owners14.46%

Ins Owner Change0%

Market Cap766.88M

Analysts78.33

Price Target18.87 (23.25%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)13.86%

Min EPS beat(2)3.68%

Max EPS beat(2)24.05%

EPS beat(4)4

Avg EPS beat(4)7.7%

Min EPS beat(4)1.1%

Max EPS beat(4)24.05%

EPS beat(8)5

Avg EPS beat(8)1.17%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-100%

Min Revenue beat(2)-100%

Max Revenue beat(2)-100%

Revenue beat(4)0

Avg Revenue beat(4)-100%

Min Revenue beat(4)-100%

Max Revenue beat(4)-100%

Revenue beat(8)1

Avg Revenue beat(8)-70.27%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-20.71%

EPS NQ rev (1m)0%

EPS NQ rev (3m)9.77%

EPS NY rev (1m)0%

EPS NY rev (3m)9.34%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)-100%

Revenue NY rev (1m)N/A

Revenue NY rev (3m)-100%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	3.3
P/tB	3.3
EV/EBITDA	N/A

EPS(TTM)-2.22

EYN/A

EPS(NY)-2.15

Fwd EYN/A

FCF(TTM)-1.47

FCFYN/A

OCF(TTM)-1.37

OCFYN/A

SpS0

BVpS4.64

TBVpS4.64

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-38.48%
ROE	-41.61%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-59.36%

ROA(5y)N/A

ROE(3y)-206.85%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	179.55%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	18.1
Quick Ratio	18.1
Altman-Z	22.57

F-Score3

WACC10.99%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)643.03%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-1.83%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%20%

EPS Next Y5.52%

EPS Next 2Y3.44%

EPS Next 3Y-1.53%

EPS Next 5Y18.96%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y3.57%

Revenue Next 5Y194.45%

EBIT growth 1Y-20.15%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-84.05%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-60.04%

OCF growth 3YN/A

OCF growth 5YN/A

ICOSAVAX INC (ICVX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens